SEC Filing Summary: SRx Health Solutions, Inc. (SRXH)
Business Context and Reporting Period
This Form 8-K Current Report, dated March 16, 2026, details a material definitive agreement entered into by SRx Health Solutions, Inc. (the "Company"). The filing reports on a private placement transaction executed on March 16, 2026, involving the issuance of Series B Convertible Preferred Stock and accompanying warrants to purchase common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Private Placement of Series B Convertible Preferred Stock and Warrants.
- Initial Proceeds: Approximately $4.528 million raised in cash at the initial closing.
- Securities Issued (Initial Closing): 5,660 shares of Series B Preferred Stock and 22,237,666 Warrants.
- Total Capacity: The agreement allows for up to 10,000 shares of Series B Preferred Stock and associated warrants for an aggregate purchase price of up to $8.0 million.
- Warrant Terms: Initial exercise price of $0.3182 per share; expire on the third anniversary of the initial exercisability date.
- Preferred Stock Terms: Stated value of $1,000 per share; ranks senior to common stock and pari passu with Series A Preferred Stock.
Material Changes and Structural Implications
The filing represents a significant capital raise and a change in the Company's capital structure. Key structural changes include:
- Conversion Rights: Series B Preferred Stock is convertible into common stock at a fixed price of $0.3182, subject to adjustments for stock splits and dividends. Post-stockholder approval, holders may convert at a lower price based on market volume-weighted averages (95% or 90% depending on triggering events).
- Triggering Events: Specific events, such as suspension of trading, failure to pay dividends, or bankruptcy, allow for alternate conversion pricing.
- Covenants: The Company is restricted from redeeming or repurchasing other capital stock, declaring dividends, or incurring new indebtedness (except ordinary trade payables) while the Series B Preferred Stock is outstanding.
- Stockholder Approval: The Company must seek stockholder approval for the issuance of common stock resulting from conversions and warrant exercises to comply with NYSE American rules.
Outlook, Risks, and Contingencies
- Future Closings: Additional closings are at the option of the investors, subject to customary conditions, potentially raising the remaining balance up to the $8.0 million cap.
- Registration Rights: The Company has entered into a Registration Rights Agreement requiring the filing of a registration statement with the SEC for the resale of common stock issuable upon conversion or exercise.
- Liquidity and Redemption: The Company has an optional right to redeem all outstanding Series B Preferred Stock in cash at 125% of the greater of the conversion amount or a market-based calculation.
- Unregistered Sales: The securities were sold in reliance on exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the total number of shares of Series B Preferred Stock issued in subsequent closings to determine if the full $8.0 million capacity was utilized.
- Confirm the date and outcome of the required stockholder approval for the issuance of common stock upon conversion.
- Review the status of the registration statement filed under the Registration Rights Agreement to assess liquidity for investors.
- Monitor the Company's compliance with covenants restricting dividends, debt, and other equity issuances.
- Check for any "Triggering Events" that may alter the conversion price of the Series B Preferred Stock.